Grand Pharmaceutical GroupCGPHF 86 Return-on-Tangible-Equity is 1.19% as of Dec. 2025, which is 94% below its 10-year median of 20.38. GuruFocus rates CGPHF with a GF Score™ of 86/100. The stock has 6 warning signs investors should review. Among 897 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 57.08% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Grand Pharmaceutical Group's annualized net income for the quarter that ended in Dec. 2025 was $18.47 Mil. Grand Pharmaceutical Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $1,550.72 Mil. Therefore, Grand Pharmaceutical Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 1.19%.
The historical rank and industry rank for Grand Pharmaceutical Group's Return-on-Tangible-Equity or its related term are showing as below:
CGPHF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.22 Med: 20.38 Max: 97.39
Current: 10.09
During the past 13 years, Grand Pharmaceutical Group's highest Return-on-Tangible-Equity was 97.39%. The lowest was 10.22%. And the median was 20.38%.
CGPHF's Return-on-Tangible-Equity is ranked better than 57.08% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs CGPHF: 10.09
Grand Pharmaceutical Group (OTCPK:CGPHF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Grand Pharmaceutical Group Return-on-Tangible-Equity Related Terms
Grand Pharmaceutical Group Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group Return-on-Tangible-Equity Chart
CGPHF vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.19% mean?
Grand Pharmaceutical Group (CGPHF) has a Return-on-Tangible-Equity of 1.19% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Grand Pharmaceutical Group and its competitors. This is 94% below median its historical median of 20.38. Over the past decade, Grand Pharmaceutical Group's Return-on-Tangible-Equity has ranged from 10.22 to 97.39. According to the industry distribution chart, Grand Pharmaceutical Group ranks #385 out of 897 companies in the Drug Manufacturers industry, placing it in the top 42.9%.
Is Grand Pharmaceutical Group's Return-on-Tangible-Equity too high?
Grand Pharmaceutical Group's current Return-on-Tangible-Equity of 1.19% is 94% below median its 10-year median of 20.38. Over the past 10 years, this metric has ranged from a low of 10.22 to a high of 97.39. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Grand Pharmaceutical Group's value of 1.19% is 84.9% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #385 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #385 out of 897 companies for Return-on-Tangible-Equity. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Grand Pharmaceutical Group's value of 1.19% is 84.9% below this benchmark. Historically, Grand Pharmaceutical Group's own Return-on-Tangible-Equity has ranged from 10.22 to 97.39 over the past decade. While the company's 10-year median is 20.38 vs. the industry median of 7.90, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Return-on-Tangible-Equity of 1.19% is 84.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Return-on-Tangible-Equity is 1.19%, which is 94% below median its own 10-year median of 20.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Return-on-Tangible-Equity of 1.19%. The current Return-on-Tangible-Equity is 1.19%, which is 94% below median its 10-year median of 20.38 and 84.9% below the Drug Manufacturers industry median of 7.90. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Return-on-Tangible-Equity is 1.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 